urse-led medication monitoring for patients with dementia and adverse events
Not Applicable
Completed
- Conditions
- Dementia, including dementia subtypesNervous System Diseases
- Registration Number
- ISRCTN48133332
- Lead Sponsor
- Swansea University (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
1. Resident at the care home
2. Diagnosed with dementia or dementia subtypes
3. Currently taking at least one of: antipsychotic or anti-epileptic or antidepressant medicine
4. Willing and be able to give informed, signed consent themselves, or if capacity is lacking, guardian or representative willing to give consent to access the patient records
Exclusion Criteria
1. Not be well enough to participate, as screened by their nurses
2. Those aged 18 or under
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Problems found and actions taken at each step in the trial. Each step is separated by one month and data will be collected using the ADR profile and case note review.
- Secondary Outcome Measures
Name Time Method This project will be used to develop a feasibility study to assess:<br>1. Rates of recruitment, retention, compliance and cross-over<br>2. Feasibility of reporting changes in documentation for:<br>2.1. Amelioration of problems found using the profile<br>2.2. Problems found and actions taken using the profile<br>2.3. Medication review or changes<br>2.4. Patients with different severity of illness<br>3. Develop clinical endpoints for a full trial, such as measures to capture changes in patients? functioning<br>4. Calculate intra-cluster correlation coefficient (ICC), and any time delay to patient benefits<br>5. Explore the basis for cost-effectiveness analysis <br>6. Report views of care home staff on the WWADR profile for mental health medicines